# EDGAR Filing Document

**Accession Number:** 0001865506
**File Stem:** 0000000000-23-001239
**Filing Date:** 2023-2
**Character Count:** 7351
**Document Hash:** bf15ab2cb389fc932c3fad4357c43fb0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001239.hdr.sgml**: 20240313

**ACCESSION NUMBER**: 0000000000-23-001239

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230207

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ESGEN Acquisition Corp
- **CENTRAL INDEX KEY:** 0001865506
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690]
- **ORGANIZATION NAME:** 04 Manufacturing
- **IRS NUMBER:** 981601409
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-40927

**BUSINESS ADDRESS:**
- **STREET 1:** 5956 SHERRY LANE, SUITE 1400
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75225
- **BUSINESS PHONE:** 214-987-6100

**MAIL ADDRESS:**
- **STREET 1:** 5956 SHERRY LANE, SUITE 1400
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75225

## Text-Extract

```

                        745 Seventh Avenue
         BARCIAYS
                        New York, NY 10019

                        United States

January 31, 2023

Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

To Whom it May Concern:

    Barclays Capital Inc. ("Barclays") was informed that ESGEN Acquisition
Corporation (the "Company") intends to pursue
a business combination with BIGREP GMBH or one of its affiliate(s) (the
"Target") (the "Business Combination"). Barclays
has not been engaged by the Company, the sponsor or the Target regarding the
Business Combination. However, because
Barclays served as one of the Company's underwriters on its initial public
offering (the "IPO"), Barclays will be entitled to its
portion of the back-end fee if the Business Combination is consummated.

    Citigroup Global Markets Inc. and Barclays Capital Inc., in each case, as
representatives of the several underwriters,
previously entered into an underwriting agreement, dated October 19, 2021 (the
"Underwriting Agreement") related to the
Company's IPO that entitles Barclays to a portion of the Deferred Discount (as
defined in the Underwriting Agreement).
Barclays informed the Company that it has waived any rights it has to the
Deferred Discount solely as it relates to the
Business Combination.

    A registration statement for the Business Combination has not filed or
confidentially submitted with the Securities and
Exchange Commission and, therefore, has not yet been declared effective as of
the date of this letter.

     This letter is to advise you that, effective as of January 31, 2023,
Barclays (i) waived any Deferred Discount solely with
respect to the Business Combination and (ii) has resigned from, or ceased or
refused to act in, every capacity and
relationship in which we may be described in any registration statement with
respect to the Business Combination as acting
or agreeing to act (including, without limitation, any capacity or relationship
(A) required to be described under Paragraph
(5) of Schedule A (15 U.S.C. 77aa) or (Bl for which consent is required under
Section 7 of the Securities Act of 1933, as
amended (the "Securities Act")) with respect to the Business Combination.

     Therefore, we hereby advise you and the Company, that pursuant to Section
ll(b)(l) of the Securities Act, that none of
our firm, any person who controls it (within the meaning of either Section 15
of the Securities Act or Section 20 of the
Securities Exchange Act of 1934, as amended) or any of its affiliates (within
the meaning of Rule 405 under the Securities
Act) will be responsible for any part of the registration statement with
respect to the Business Combination. This notice is
not intended to constitute an acknowledgment or admission that we have been or
are an underwriter (within the meaning
of Section 2(a)(ll) of the Securities Act or the rules and regulations
promulgated thereunder) with respect to the Business
Combination.

                                                                Sincerely,

                                                                BARCLAYS
CAPITAL INC.

                                                                By: _
,-.,...........,......,__ ~~---
                                                                Name:
                                                                Title: M

29225864V2

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

745 Seventh Avenue  
New York, NY 10019  
United States

January 31, 2023

Securities and Exchange Commission

To Whom it May Concern:

Barclays Capital Inc. (“Barclays”) was informed that ESGEN Acquisition Corporation (the “Company”) intends to pursue a business combination with BIGREP GMBH or one of its affiliate(s) (the “Target”) (the “Business Combination”). Barclays has not been engaged by the Company, the sponsor or the Target regarding the Business Combination. However, because Barclays served as one of the Company’s underwriters on its initial public offering (the “IPO”), Barclays will be entitled to its portion of the back-end fee if the Business Combination is consummated.

Citigroup Global Markets Inc. and Barclays Capital Inc., in each case, as representatives of the several underwriters, previously entered into an underwriting agreement, dated October 19, 2021 (the “Underwriting Agreement”) related to the Company’s IPO that entitles Barclays to a portion of the Deferred Discount (as defined in the Underwriting Agreement). Barclays informed the Company that it has waived any rights it has to the Deferred Discount solely as it relates to the Business Combination.

A registration statement for the Business Combination has not filed or confidentially submitted with the Securities and Exchange Commission and, therefore, has not yet been declared effective as of the date of this letter.

This letter is to advise you that, effective as of January 31, 2023, Barclays (i) waived any Deferred Discount solely with respect to the Business Combination and (ii) has resigned from, or ceased or refused to act in, every capacity and relationship in which we may be described in any registration statement with respect to the Business Combination as acting or agreeing to act (including, without limitation, any capacity or relationship (A) required to be described under Paragraph (5) of Schedule A (15 U.S.C. 77aa) or (B) for which consent is required under Section 7 of the Securities Act of 1933, as amended (the “Securities Act”)) with respect to the Business Combination.

Therefore, we hereby advise you and the Company, that pursuant to Section 11(b)(1) of the Securities Act, that none of our firm, any person who controls it (within the meaning of either Section 15 of the Securities Act or Section 20 of the Securities Exchange Act of 1934, as amended) or any of its affiliates (within the meaning of Rule 405 under the Securities Act) will be responsible for any part of the registration statement with respect to the Business Combination. This notice is not intended to constitute an acknowledgment or admission that we have been or are an underwriter (within the meaning of Section 2(a)(11) of the Securities Act or the rules and regulations promulgated thereunder) with respect to the Business Combination.

Sincerely,

BARCLAYS CAPITAL INC.

By:

Name:

Title: Managing Director

29225864V2